SHANGHAI & TEL AVIV, Israel - Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a subsidiary of global pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), has announced a new partnership with Jiangsu Nhwa Pharmaceutical Co., Ltd. This alliance focuses on the marketing and distribution of AUSTEDO, a treatment for neurodegenerative and movement disorders, specifically chorea related to Huntington's disease (HD) and tardive dyskinesia (TD) in adults.
The collaboration aims to leverage Nhwa's expertise in China's neuro-psychiatric sector to improve access to AUSTEDO for patients in the region. Huntington's disease is a rare, fatal neurodegenerative condition characterized by involuntary, random muscle movements known as chorea, which affects up to 90% of adults with the disease. Tardive dyskinesia is a side effect of long-term antipsychotic medication, resulting in repetitive, uncontrollable movements, with a higher prevalence in China compared to the global average.
AUSTEDO, which is the first deuterated drug approved in China, employs deuterium technology to potentially reduce metabolism rates and allow less frequent dosing for patients. Theodor Wee, General Manager of Teva Greater China, emphasized the partnership's potential to promote the cost-effective delivery of quality medicines and contribute to the sustainability of China's healthcare system.
Mark Sabag, EVP and Head of International Markets at Teva, highlighted the partnership as a step in growing AUSTEDO as a global brand, which generated over $1.2 billion in revenues in 2023, and aligns with Teva's "Pivot to Growth" strategy.
AUSTEDO is the only VMAT2 inhibitor approved by the U.S. Food and Drug Administration for the treatment of TD and chorea associated with HD in adults.
Jiangsu Nhwa Pharmaceutical, a leading CNS company in China, brings over 40 years of dedication to the development of innovative treatments in psychiatry and neurology. The company has a comprehensive range of capabilities from research and development to commercialization.
This article is based on a press release statement and contains forward-looking statements that involve risks and uncertainties. The future results and achievements of Teva and its partnership with Nhwa could differ from current expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.